Global Diagnostics Leader Diasorin’s broad in vitro diagnostic (IVD) portfolio and life science offerings across 35 companies, 10 manufacturing facilities, and 9 R&D centers positions it as a comprehensive partner for lab infrastructure, reagents, and workflow optimization in large healthcare systems.

Expanded Global Footprint With operations on five continents and a workforce exceeding 3,200 including 400 researchers, there are substantial cross-border sales opportunities for reagents, kits, and related services in both established and emerging markets.

R&D Centric Growth Significant investments in research and development suggest ongoing new test panels and improved assay workflows, presenting upsell opportunities for advanced diagnostic kits, automation-friendly reagents, and data analytics solutions.

Life Science Synergy Diasorin’s expansion into Life Science since 2021 creates potential for selling supplementary research reagents, reference materials, and instrument-compatible kits to academic labs and biotech customers seeking end-to-end solutions.

Digital and Compliance Readiness Adoption of modern collaboration and compliance tools (SharePoint, DocuSign, Informatica, Zoom) indicates readiness for digital procurement, e-commerce partnerships, and integrated supplier programs that streamline ordering, validation, and regulatory documentation.